May 21, 2024
Home CHF
Finance

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

  • May 21, 2024

Idorsia Pharmaceuticals Ltd Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of Idorsia Asia-Pacific operations (excluding China): Sold to Nxera Pharma (previously known as Sosei Heptares) for a total consideration of CHF

Read More
Finance

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

  • April 18, 2024

Addex Therapeutics Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR

Read More